This experimental drug offers a glimmer of hope in the treatment of pancreatic cancer, which is among the deadliest types of cancer, after initial clinical trials showed a reduction in tumor size in some patients.
Daraxonrasib drug:
This drug, named “Daraxonrasib” and developed by “Revolution Medicines,” has been granted a fast-track review by the US Food and Drug Administration in order to expedite its availability to patients. This step has sparked widespread controversy about how quickly approvals should be issued without compromising safety standards.
Trial data shows that 29% of patients experienced tumor shrinkage, while tumor growth stopped in more than 90% of participants. This rate is considered much better compared to the results of traditional treatments, although side effects were recorded in the majority of trial participants.
The drug relies on targeting mutations in RAS genes that stimulate cancer cell growth, which represents a scientific breakthrough that was considered impossible for many years.
Researchers believe that the drug may represent a “turning point” in the treatment of pancreatic cancer, but they emphasize the need to await the results of larger trials, which are expected to be released next year, to determine whether the drug will actually make a radical change in the face of this aggressive type of cancer.
(Translations)
